Pfizer Grows In Rare Disease With $810m Dwarfism Company Buy
Executive Summary
Pfizer adds to its rare disease portfolio with purchase of Therachon, a Swiss company working in achondroplasia. But whether it can catch up with Biomarin’s Phase III vosoritide is still to be seen.
You may also be interested in...
VectivBio Seeks Slice Of Short Bowel Syndrome Market
The Switzerland-headquartered group believes it has a potentially best-in-class GLP-2 agonist on its hands with apraglutide, which has proved effective in a subgroup of patients that do not benefit from standard of care Gattex.
VectivBio Grabs Tail Of Comet Therapeutics In New Rare Disease Play
Deal Snapshot: VectivBio is expanding its existing focus on rare diseases into inherited metabolic disorders, which affect about one in 800 live births and cause significant mortality in infants and young people.
J.P. Morgan Notebook Day 2: Bourla Feels Pfizer's Underappreciated, GSK Prepares For Myeloma First And More
Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: GSK's first-in-class oncology opportunity, Pfizer's Bourla on underappreciated pipeline, AstraZeneca's Enhertu pricing, Amgen's genomics push, Lilly filters through deals and Medicxi's de Rubertis teases big pharma CEOs about M&A.